Ruth March
Impact in
- Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism
-
- Computational Drug Discovery Methods
Papers in
- Genetics 9
- Genetic Associations and Epidemiology 3
- Genomics and Rare Diseases 3
-
- T-cell and B-cell Immunology 2
- Co-authors
- Menelas N. Pangalos (2 shared papers)Paul Morgan (2 shared papers)Robert Alexander (1 shared paper)David Cook (1 shared paper)Dearg S. Brown (1 shared paper)Eminy H.Y. Lee (1 shared paper)Yu Chen (1 shared paper)Dennis W. Schneck (1 shared paper)
- Journals
- Pharmacogenomics (3 papers)Yeast (2 papers)Nature Reviews Drug Discovery (2 papers)Scientific Reports (1 paper)Journal of Neurochemistry (1 paper)
- Partner nations
- United KingdomUnited StatesSweden
In The Last Decade
Ruth March
29 papers receiving 2.0k citations
Ruth March's Hit Papers
Peers
Comparison fields: 5 of 132
- Pharmacology 280
- Computational Theory and Mathematics 359
- Immunology 300
- Rheumatology 173
- Statistics and Probability 82
Countries citing papers authored by Ruth March
This map shows the geographic impact of Ruth March's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth March with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth March more than expected).
Fields of papers citing papers by Ruth March
This network shows the impact of papers produced by Ruth March. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth March. The network helps show where Ruth March may publish in the future.
Co-authors
The 25 scholars most cited alongside Ruth March, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework Hit paper breakdown → | 2014 | 891 |
| 2 | 2005 | 372 | |
| 3 | Impact of a five-dimensional framework on R&D productivity at AstraZeneca Hit paper breakdown → | 2018 | 271 |
| 4 | 1998 | 114 | |
| 5 | 2004 | 73 | |
| 6 | 1998 | 62 | |
| 7 | 2006 | 46 | |
| 8 | 2001 | 36 | |
| 9 | 2000 | 33 | |
| 10 | 2002 | 25 | |
| 11 | 2000 | 22 | |
| 12 | 1995 | 22 | |
| 13 | 1999 | 18 | |
| 14 | 2022 | 14 | |
| 15 | 1959 | 11 | |
| 16 | 2010 | 11 | |
| 17 | 1956 | 11 | |
| 18 | 2005 | 9 | |
| 19 | 2011 | 9 | |
| 20 | 2001 | 8 |
About Ruth March
Ruth March is a scholar working on Genetics, Immunology, Molecular Biology, Pharmacology and Oncology, having authored 29 papers that have together received 2.1k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (6 papers), Computational Drug Discovery Methods (4 papers), Genetic Associations and Epidemiology (3 papers), Genomics and Rare Diseases (3 papers), Pharmaceutical Economics and Policy (3 papers), Pharmaceutical studies and practices (2 papers), T-cell and B-cell Immunology (2 papers) and Rheumatoid Arthritis Research and Therapies (2 papers). The work is most often cited by research in Pharmacology (280 citations), Computational Theory and Mathematics (359 citations), Immunology (300 citations), Rheumatology (173 citations) and Statistics and Probability (82 citations). Ruth March has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include Menelas N. Pangalos, Paul Morgan, Robert Alexander, David Cook, Dearg S. Brown, Eminy H.Y. Lee, Yu Chen, Dennis W. Schneck, Caroline Lee and S RYAN. Their work appears in journals such as Pharmacogenomics, Yeast, Nature Reviews Drug Discovery, Scientific Reports and Journal of Neurochemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.